Orchid Pharma Limited – Investor Presentation Summary
Key Operational Highlights
- EXBLIFEP positioned as India's only novel antibiotic and only USFDA-approved sterile cephalosporin
- Built on 30 years of cephalosporin expertise with expansion into AMR and regulated markets
- Two entities merged into one Orchid: Dhanuka Laboratories Ltd. amalgamated into Orchid Pharma Ltd. effective April 1, 2024 under NCLT-sanctioned Scheme
Key drivers of operational performance: EXBLIFEP business development through licensing partnerships
Segment-wise Performance
Not Specified
Financial Highlights
Revenue: ₹341.27 Cr (Q2 FY27), ₹645.44 Cr (H1 FY27)
EBITDA: ₹52 Cr (Q2 FY27), ₹77 Cr (H1 FY27)
PAT: ₹36.76 Cr (Q2 FY27), ₹48.70 Cr (H1 FY27)
EPS: ₹6.14 (Q2 FY27), ₹8.13 (H1 FY27)
Margins: EBITDA Margin 15% (Q2 FY27), 12% (H1 FY27)
YoY/QoQ comparison: Q2 FY27 revenue +14% YoY, EBITDA +148% YoY; H1 FY27 revenue +15% YoY, EBITDA +151% YoY
Drivers of financial performance: Revenue growth, operational efficiencies
Comparison to market estimates: Not Specified
Key Risks: Not Specified
Geographical Revenue Split
Domestic vs Export/Regional Revenue: Not Specified
Regional Breakdown: Not Specified
Balance Sheet Snapshot
Net Debt/Equity: Debt/Equity ratio 0.33x (Consolidated, Sep 2026)
Reserves: Other equity ₹1,633.14 Cr (Standalone, Sep 2026)
Current Assets/Liabilities: Current assets ₹877.95 Cr, Current liabilities ₹550.60 Cr (Standalone, Sep 2026)
Working Capital/Leverage Metrics: Not Specified
Financial Health Insights: Total assets increased to ₹2,652 Cr from ₹2,258 Cr (Mar 2026)
Capex & Cash Flow Health
Capital Expenditure: Capital work-in-progress ₹196.12 Cr (Standalone, Sep 2026), Intangibles under development ₹15.85 Cr (Standalone, Sep 2026)
Free Cash Flow: Not Specified
Operating Cash Flow: Net cash from operating activities ₹90.71 Cr (Standalone H1 FY27), ₹117.78 Cr (Consolidated H1 FY27)
Net Debt Movement: Gross borrowings increased to ₹544 Cr from ₹301 Cr (Mar 2026)
Investment Rationale: Capacity expansion and intangible development
Strategic & R&D Initiatives
Investments in Innovation: EXBLIFEP - India's only novel antibiotic platform
Expected impact on growth: Licensing partnerships estimated at $80M sales potential
Strategic Rationale: Expanding into AMR and regulated markets through partnerships
Industry Trends & Business Environment
Macro/Industry Trends: Antimicrobial Resistance (AMR) focus
Impact on Company: Positioning as integrated anti-infective platform globally
Management Commentary & Growth Outlook
Strategic Outlook: Not Specified
FY Guidance: Not Specified
Market Share Targets: Not Specified
Risks and Opportunities: Not Specified